OraSure Technologies, Inc. (OSUR) Scheduled to Post Earnings on Tuesday
OraSure Technologies, Inc. (NASDAQ:OSUR) is scheduled to be posting its quarterly earnings results on Tuesday, October 31st. Analysts expect OraSure Technologies to post earnings of $0.08 per share for the quarter. OraSure Technologies has set its Q3 guidance at $0.09-0.10 EPS.
OraSure Technologies (NASDAQ:OSUR) last announced its earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.09 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.07 by $0.02. OraSure Technologies had a return on equity of 15.64% and a net margin of 22.29%. The company had revenue of $40.18 million for the quarter, compared to analyst estimates of $36.54 million. During the same period in the prior year, the company posted $0.07 EPS. The firm’s quarterly revenue was up 28.1% compared to the same quarter last year. On average, analysts expect OraSure Technologies to post $0.42 EPS for the current fiscal year and $0.39 EPS for the next fiscal year.
OraSure Technologies, Inc. (NASDAQ OSUR) opened at 20.39 on Tuesday. OraSure Technologies, Inc. has a 12 month low of $7.09 and a 12 month high of $23.01. The company’s 50-day moving average price is $21.66 and its 200 day moving average price is $17.88. The firm has a market capitalization of $1.21 billion, a price-to-earnings ratio of 37.69 and a beta of 1.55.
A number of analysts have issued reports on OSUR shares. Jefferies Group LLC lifted their price target on OraSure Technologies from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, June 28th. Canaccord Genuity boosted their target price on OraSure Technologies from $15.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday, June 28th. BidaskClub downgraded OraSure Technologies from a “strong-buy” rating to a “buy” rating in a report on Monday, July 24th. Finally, Zacks Investment Research raised OraSure Technologies from a “hold” rating to a “buy” rating and set a $24.00 target price for the company in a report on Saturday, September 9th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $18.54.
In related news, insider Brian Smith sold 3,075 shares of the business’s stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $21.09, for a total value of $64,851.75. Following the transaction, the insider now owns 24,540 shares in the company, valued at approximately $517,548.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Douglas A. Michels sold 22,923 shares of the business’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $23.00, for a total value of $527,229.00. The disclosure for this sale can be found here. Insiders sold a total of 717,601 shares of company stock valued at $14,977,398 over the last three months. Company insiders own 6.40% of the company’s stock.
OraSure Technologies Company Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.